GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jeil Pharma Holdings Inc (XKRX:002620) » Definitions » Equity-to-Asset

Jeil Pharma Holdings (XKRX:002620) Equity-to-Asset : 0.36 (As of Mar. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Jeil Pharma Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Jeil Pharma Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩319,251 Mil. Jeil Pharma Holdings's Total Assets for the quarter that ended in Mar. 2024 was ₩880,607 Mil. Therefore, Jeil Pharma Holdings's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.36.

The historical rank and industry rank for Jeil Pharma Holdings's Equity-to-Asset or its related term are showing as below:

XKRX:002620' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33   Med: 0.47   Max: 0.84
Current: 0.36

During the past 13 years, the highest Equity to Asset Ratio of Jeil Pharma Holdings was 0.84. The lowest was 0.33. And the median was 0.47.

XKRX:002620's Equity-to-Asset is ranked worse than
74.61% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs XKRX:002620: 0.36

Jeil Pharma Holdings Equity-to-Asset Historical Data

The historical data trend for Jeil Pharma Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeil Pharma Holdings Equity-to-Asset Chart

Jeil Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.46 0.46 0.39 0.36

Jeil Pharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.39 0.38 0.36 0.36

Competitive Comparison of Jeil Pharma Holdings's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Jeil Pharma Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jeil Pharma Holdings's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jeil Pharma Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Jeil Pharma Holdings's Equity-to-Asset falls into.



Jeil Pharma Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Jeil Pharma Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=319461.151/879996.991
=0.36

Jeil Pharma Holdings's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=319250.674/880606.892
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeil Pharma Holdings  (XKRX:002620) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Jeil Pharma Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Jeil Pharma Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Jeil Pharma Holdings (XKRX:002620) Business Description

Traded in Other Exchanges
N/A
Address
745-5, Banpo-dong, Seocho-gu, Seoul, KOR, 137-810
Jeil Pharma Holdings Inc is involved in manufacture and distribution of pharmaceutical products. The company mainly produces finished pharmaceutical products and active pharmaceutical ingredients. It has categorized its products in Antibiotic, Oncology, Cardiovascular, Gastrointestinal, Urology, Respiratory etc. The firm's manufacturing facility and research and development institute located at Yongin-si, Gyeonggi-do in Korea.

Jeil Pharma Holdings (XKRX:002620) Headlines

No Headlines